

ENDOCARE INC  
Form 424B3  
February 16, 2006

**Prospectus Supplement No. 7 to Prospectus dated September 28, 2005**  
**Filed Pursuant to Rule 424(b)(3)**  
**Registration Statement No. 333-123866**

**Endocare, Inc.**  
**Supplement No. 7**  
**to**  
**Prospectus Dated September 28, 2005**

This is a Supplement to Endocare, Inc.'s Prospectus, dated September 28, 2005, with respect to the offer and sale of up to 9,580,126 shares of our common stock by the selling stockholders listed in the Prospectus or their transferees. This Supplement amends and supplements certain information contained in the Prospectus. You should read this Supplement carefully.

Endocare, Inc. is a specialty medical device company focused on improving patients' lives through the development, manufacturing and distribution of health care products for cryoablation. Our strategy is to achieve a dominant position in the prostate and renal cancer markets, further developing and increasing the acceptance of our technology in the interventional radiology and oncology markets for treatment of liver and lung cancers and management of pain from bone metastases, while achieving penetration across additional markets with our proprietary cryosurgical technology. The term "cryoablation" refers to the use of ice to destroy tissue, such as tumors, for therapeutic purposes. The term "cryosurgical technology" refers to technology relating to the use of ice in surgical procedures, including cryoablation procedures.

Our common stock is traded on the Over-the-Counter Bulletin Board, or OTCBB, under the symbol ENDO. On February 15, 2006, the last reported sale price of our common stock on the OTCBB was \$3.28 per share.

**YOU SHOULD CAREFULLY CONSIDER THE RISK FACTORS FOR OUR SHARES, WHICH ARE LISTED IN THE PROSPECTUS.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under this Supplement and the Prospectus or determined if this Supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

**The date of this prospectus supplement is February 16, 2006**

---

**CURRENT REPORT ON FORM 8-K**

On February 16, 2006, we filed with the SEC a Current Report on Form 8-K relating to:  
the closing of our sale to Plethora Solutions Holdings plc of all of the stock of our wholly-owned subsidiary, Timm Medical Technologies, Inc.; and

our entry into a related Amendment to Loan Documents with Silicon Valley Bank.

We hereby incorporate by reference into this Supplement and the Prospectus the Current Report on Form 8-K filed with the SEC on February 16, 2006.

A copy of our Current Report on Form 8-K filed on February 16, 2006 is being provided to you along with this Supplement.

Information about other documents that have been incorporated by reference into the Prospectus is included in the section of the Prospectus captioned Where You Can Find More Information.

**Prospectus Supplement dated February 16, 2006**